""This is really disruptive," said Mariana Socal, a health policy professor at Johns Hopkins University. "This is bringing real competition to the market. It's really opening up new possibilities for patients and plans.""
""I just wasn't making money to be able to shell out hundreds of dollars every two weeks for my insulin," he said. Now that he has insurance, he's relieved to have CalRx as a backup. "Let's say I forget a vial at home or a vial breaks, the clock starts ticking until I start feeling symptoms. So just knowing that I can go to a retail pharmacy and purc"
California will launch a state-run drug label, CalRx, to sell insulin glargine pens beginning Jan. 1, 2026, at a suggested maximum retail price of $55 per five-pack ($11 per pen). The program bypasses the leading insulin manufacturers and pharmacy middlemen to provide lower-cost generic insulin directly through retail pharmacies. Each vial will display a QR code linking to the $55 maximum price to reveal any plan or pharmacy markups and increase pricing transparency. The initiative challenges dominant manufacturers that control roughly 90% of the U.S. insulin market and aims to expand competition, affordability, and backup access for people with diabetes.
Read at Kqed
Unable to calculate read time
Collection
[
|
...
]